• Interius BioTherapeutics

  Participated · Series A · May 2021

  Interius BioTherapeutics is a preclinical-stage gene therapy company based in Philadelphia focused on an in vivo cell-specific gene delivery platform. Its lead program aims to generate chimeric antigen receptor (CAR) T cells directly in patients, bypassing ex vivo cell manipulations and the potentially toxic pre-conditioning chemotherapy used in standard CAR T treatments. The company says the platform is versatile and it is developing applications beyond immuno-oncology for diseases not amenable to current gene therapy modalities. Interius was co-founded by Dr. Saar Gill and Bruce Peacock and is led by CEO Phil Johnson, MD. The company intends to use new funding to expand its development efforts. No operating metrics were disclosed in the article.

No current team members are available.